Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer

• Published in: Molecular biology reports Vol. 41; no. 9; pp. 6125 - 6131
• Main Authors: Mahdian, Reza, Nodouzi, Vahideh, Asgari, Mojgan, Rezaie, Mitra, Alizadeh, Javad, Yousefi, Behzad, Shahrokh, Hossein, Abolhasani, Maryam, Nowroozi, Mohamadreza
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer-Verlag 01-09-2014; Springer Netherlands; Springer Nature B.V
• Subjects: Aged; Animal Anatomy; Animal Biochemistry; Antigens, Neoplasm - genetics; Antigens, Neoplasm - metabolism; Biomarkers; Biomedical and Life Sciences; Carrier Proteins - genetics; Carrier Proteins - metabolism; Cell Line, Tumor; Disease Progression; Down-Regulation; Gene Deletion; Gene expression; gene expression regulation; Gene Expression Regulation, Neoplastic; Genes; Genetic Markers; Histology; Homeodomain Proteins - genetics; Homeodomain Proteins - metabolism; Humans; hyperplasia; Iran; Life Sciences; loci; Male; Membrane Proteins - genetics; Membrane Proteins - metabolism; messenger RNA; Middle Aged; Morphology; Prostate - cytology; Prostate - pathology; Prostate cancer; Prostatic Hyperplasia - genetics; prostatic neoplasms; Prostatic Neoplasms - genetics; PTEN Phosphohydrolase - genetics; PTEN Phosphohydrolase - metabolism; Racemases and Epimerases - genetics; Racemases and Epimerases - metabolism; Trans-Activators - genetics; Trans-Activators - metabolism; Transcription Factors - genetics; Transcription Factors - metabolism; Transcriptional Regulator ERG; Transcriptome; Trypsin Inhibitor, Kazal Pancreatic; Iran; PTEN; BPH; Gene expression; Prostate cancer; MAGI2
• ISSN: 0301-4851; 1573-4978
• DOI: 10.1007/s11033-014-3491-0

Complex molecular changes that occur during prostate cancer (PCa) progression have been described recently. Whole genome sequencing of primary PCa samples has identified recurrent gene deletions and rearrangements in PCa. Specifically, these molecular events disrupt the gene loci of phosphatase and tensin homolog (PTEN) and membrane-associated guanylate kinase inverted-2 (MAGI2). In the present study, we analyzed the expression profile of MAGI2 gene in a cohort of clinical PCa (n = 45) and benign prostatic hyperplasia (BPH) samples (n = 36) as well as three PCa cell lines. We also studied the expression of PCa-related genes, including PTEN, NKX3.1, SPINK1, DD3, AMACR, ERG, and TMPRSS2-ERG fusion in the same samples. The expression of MAGI2 mRNA was significantly down-regulated in PC3, LNCaP and DU-145 PCa cell lines (p = 0.000), and also in clinical tumor samples (Relative expression = 0.307, p = 0.002, [95 % CI 0.002–12.08]). The expression of PTEN, NKX3.1, SPINK1, DD3, and AMACR genes was significantly deregulated in prostate tumor samples (p range 0.000–0.044). A significant correlation was observed between MAGI2 and NKX3.1 expression in tumor samples (p = 0.006). Furthermore, the inclusion of MAGI2 in the gene panel improved the accuracy for discrimination between PCa and BPH samples with the sensitivity and specificity of 0.88 [CI 0.76–0.95] and 0.83 [CI 0.68–0.92], respectively. The data presented here suggest that MAGI2 gene can be considered as a novel component of gene signatures for the detection of PCa.